Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Shattuck Labs Inc STTK

Healthcare Biotechnology
Shattuck Labs, Inc. is a clinical-stage biotechnology company. The Company is engaged in the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease. Its lead product candidate, SL-172154, is designed to simultaneously inhibit the CD47/SIRPa macrophage checkpoint interaction and activate the CD40 costimulatory receptor to induce an antitumor immune response. It is conducting a Phase IA/B clinical trial in patients with acute myeloid leukemia (AML) and HR-MDS. It has completed the Phase IA dose-escalation portion of this clinical trial and are enrolling patients in the Phase IB expansion cohorts evaluating SL-172154 in combination with azacitidine in frontline HR-MDS or frontline TP53 mutant (TP53m) AML. It has developed the ARC platform to address the need for a single therapeutic that consolidates multiple immune functions.


NDAQ:STTK - Post by User

Shattuck Labs Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(291)
•••
Post by whytestockson Oct 14, 2024 6:15pm
42 Views
Post# 36265621

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs,

Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs,
Just In: $STTK Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities InvestigationNEW YORK CITY, NY / ACCESSWIRE / October 14, 2024 / Bronstein, Gewirtz &amp; Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. ("Shattuck" or "the Company") (NASDAQ:STTK). Investors who purchased Shattuck securities are encouraged to obtain additional...STTK - Bronstein, Gewirtz & Grossman, LLC Encourages Shattuck Labs, Inc. (STTK) Investors to Inquire about Securities Investigation

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities